Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- May 6, 2011 - Dec 2, 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study, according to GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Details on test material:
- - Name of test material (as cited in study report): XP-7866
- Analytical purity: 99.5
- Purity test date: 16.05.2011
- Lot/batch No.: 10188-1 JM
- Expiration date of the lot/batch: 28.02.2015
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: human
- Details on mammalian cell type (if applicable):
- Primary lymphocytes from suitable donors. The cell cycle time was determined by BrdU (bromodeoxyuridine) incorporation to assess the average generation time (AGT) and the number of first, second and third division metaphase cells.
- Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbitone and ß-Naphthoflavone induced rat liver S9-preparation from male Sprague-Dawley rats.
- Test concentrations with justification for top dose:
- The test concentrations were selscted following a preliminary cytotoxicity test.
Experiment 1 and 2 without and with S9: 0, 17.92, 35.84, 71.69, 143.38, 286.75, 573.5, 1147, 2294 micro-g/ml - Vehicle / solvent:
- Dimethylsulfoxide (DMSO) 99.9%. The solvent was chosen as the test item produced a suspension suitable for dosing in this vehicle.
Controls
- Untreated negative controls:
- yes
- Remarks:
- solvent control
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: without S9: mitomycin C, with S9 Cyclophosphamide
- Details on test system and experimental conditions:
- CELL CULTURE: cells were grown in Eagles minimal essential medium with HEPES buffer supplemented with glutamine, penicillin/streptomycin, amphotericin B and 10% foetal bovine serum at 37 deg. C with 5% CO2 humidified air. the lymphocytes of fresh heparinised blood were stimulated to divide by addtion of phythaemagglutinin (PHA).
DURATION
- Exposure duration:
without S9: Experiment 1: 4 h, Experiment 2: 24 h
with S9: Experiment 1 and 2: 4 h
- Expression time (cells in growth medium): 20 h
- Fixation time (start of exposure up to fixation or harvest of cells): With metabolic activation: 24 h, without metabolic activation Experiment 1 24 h, experiment 2 44 h
SPINDLE INHIBITOR (cytogenetic assays): Demeclocine (Colcemid 0.1 micro-g/ml) applied 2 h before harvest time
STAIN (for cytogenetic assays): Giemsa (5%)
NUMBER OF REPLICATIONS: duplicate cultures per concentration
NUMBER OF CELLS EVALUATED: 100 well spread metaphases from each culture.
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index from 2000 lymphocylte cell nuclei.
OTHER EXAMINATIONS:
- Determination of polyploidy: yes cells with 69 chromosomes otr more.
. - Evaluation criteria:
- A positive response is reported for a particular treatment if the percentage of cells with aberrations other than gaps markedly exceeded that seen in concurrent controls with or without a clear dose-response relationship. For modest increases in aberration frequency a dose response relationship is generally required and statistical tests may be applied.
- Statistics:
- Fishers exact test was used to compare frequencies of cells with aberrations excluding gaps and frequency of polyploid cells with concurrent vehicle controls.
Results and discussion
Test results
- Species / strain:
- lymphocytes: human, primary
- Metabolic activation:
- with and without
- Genotoxicity:
- not specified
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: Aprecipitation of the test article was observed in the preliminary test at the end of the exposure period at a concentration of 35.84 micro-g/ml and above. In the main study precipitation was observed at the end of the treatment period at and above 143.38 micro-g/ml and above 17.92 micro-g/ml in cell pellets durign the washing procedure.
- Other confounding effects:
RANGE-FINDING/SCREENING STUDIES:
In the preliminary study the test item showed evidence of cytotoxicity in all 3 exposure groups, but no clear dose response was observed. Countable metaphases were present up to 2294 micro-g/ml. This concentration was also the maximum obtainable concentration in the vehicle.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Up to the maximum practiclly obtainable concentration of 2294 micro-g/l 50% inhibition of growth was not achieved. In experiment 1 a maximum of 16% inhibition was achieved in the absence of S9 at 573.5 micro-g/ml and 25% inhibition at 34.84 micro-g/ml in the presence of S9.
All of the vehicle control cultures had frequencies of cells with chromosomal aberrations in the expected range. The positive control items incuded statistically significant increases in the frequency of cells with aberrations.
In both replicate experiments the test item did not induce any statistically signinficant increases in frequency of cells with aberrations, either in presece or absence of metabolic activation. The test item did not induce statistically significant increases in the numbe rof polyploid cells at any dose level in any of the exposure groups. - Remarks on result:
- other: other: Primary lymphocytes from suitable donors. The cell cycle time was determined by BrdU (bromodeoxyuridine) incorporation to assess the average generation time (AGT) and the number of first, second and third division metaphase cells.
- Remarks:
- Migrated from field 'Test system'.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
negative with and without metabolic activation
Under the conditions of this test the test item did not induce any significant increase in chromosomal aberrations or polyploidie, both in the presence and absence of a metabolic activation system and was therefore not clastogenic in human lymphocytes in vitro. - Executive summary:
The test item was for its ability to induce chromosomal aberrations in vitro in cultured mammalian cells. The study was performed according to OECD TG No. 473 (1997) and EU Method B.10 (2008) and under GLP conditions. Duplicate cultures of primary human lymphocytes treated with the test item at 4 concentration levels and including positive and negative contols were evaluated for the induction of chromosomal aberrations with and without a metabolic activation system. In experiment 1 a 4 h exposure period followed by a 20 h expression period both with and without metabolic activation was performed, while in experiment 2 the exposure time without metabolic activation was prolonged to 24 hours. Cytotxicity was assessed by determining the mitotic index of 2000 lymphocyte nuclei. For the assessment of chromosomal aberrations 100 metaphases from each culture (200 per concentration) were counted. The negative and positive controls gave results in the expected ranges. The test item did not induce any significant increase in chromosomal aberrations or polyploidie in any of the experiments at any dose level with and without metabolic activation. Therfore the test item is considered to be non-clastogenic to human lymphocytes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Embora a ECHA disponibilize muito material em linha na sua língua, uma parte desta página está disponível apenas em inglês. Mais informações sobreas práticas de multilinguismo da ECHA.
Bem-vindo ao sítio Web da ECHA O navegador Internet Explorer 7 (e versões anteriores) não é totalmente suportado por este sítio Web. Por favor atualize o seu Internet Explorer para uma versão mais recente.
Este sítio Web utiliza cookies a fim de garantir a melhor experiência possível nos nossos sítios Web.
Saiba mais sobre como utilizar cookies.